Review Reports
- Natalya Andreeva 1,
- Svetlana Moiseeva 2 and
- Emmanuel Kabwe 1,3,*
- et al.
Reviewer 1: Kamalendra Singh Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis manuscript by Andreeva et al presents the results of a pilot study aimed at identifying clinical parameters that dominate in People Living With HIV (PLWH) and have COVID-19. The hematology parameters (interleukins, CCRs, etc.) were compared among patients with PLWH/COVID-19, patients with COVID-19 only, and healthy controls. The authors identified certain ILs/CCRs that were elevated in the PLWH/COVID-19 group compared to the COVID-19 group or the control group. These parameters were used to define the severity of COVID-19 disease among patients with PLWH/COVID-19. While interesting, this study has several drawbacks, as discussed below. The
- First and foremost, the cohort is too small to draw meaningful conclusions. While the authors acknowledge that it is a pilot study (as stated in the title), they should also mention this fact as a limitation of the study.
- The authors must define disease severity - It is unclear what parameters are associated with disease severity. Therefore, making comments without defining the disease severity associated with elevated ILs is difficult to understand
- The results, the way they are presented, are quite confusing. A glaring example of confusion is the paragraph that starts on line 263 and ends at line 274. There are statements that appear to contradict each other. At one point, 14 ILs were listed for increase, whereas later on, only 4 ILs were mentioned as increased in the PLWH/COVID-19 group.
- Of the 9 HIV patients, the viral RNA in 4 patients was undetected. What was the difference in ILs of the two groups, and how was undetectable RNA associated with COVID-19 severity? Additionally, it becomes more important to present the cART components when viral RNA cannot be detected, as some of the ART components are directly related to IL level.
- It is not clear why phylogenetic analysis was presented. It appears to have no connection to the main focus of the study. If the authors believe there is a relationship, it should be clearly outlined.
- Line 94. It is not that patients were collected. It should be 'the patient samples' were collected.
- Minor - Line 84: The reference is missing. It just states (ref).
English language should be checked by someone expert.
Author Response
We would like to thank the reviewer for reading our manuscript and for the constructive comments. We have addressed all the reviewers comments, as detailed below. And all the changes made in the manuscript are highlighted in yellow.
Comment 1: First and foremost, the cohort is too small to draw meaningful conclusions. While the authors acknowledge that it is a pilot study (as stated in the title), they should also mention this fact as a limitation of the study.
Response 1: We agree with the reviewer. This particular limitation is acknowledged in the paragraph lines 207–213 and the text is highlighted in yellow in the manuscript
Comment 2: The authors must define disease severity - It is unclear what parameters are associated with disease severity. Therefore, making comments without defining the disease severity associated with elevated ILs is difficult to understand
Response 2: We appreciate the reviewer’s insightful remark. Disease severity was defined according to WHO COVID-19 clinical criteria (SpO₂ thresholds, respiratory rate, CT lung injury stages, and ICU requirement). The criteria used is defined in the methods: lines 306-311 and the baseline characteristics of study participants is given in table 1. The text is highlighted in yellow.
Comment 3: The results, the way they are presented, are quite confusing. A glaring example of confusion is the paragraph that starts on line 263 and ends at line 274. There are statements that appear to contradict each other. At one point, 14 ILs were listed for increase, whereas later on, only 4 ILs were mentioned as increased in the PLWH/COVID-19 group.
Response 3: We thank the reviewer for this valuable comment. We understand that the initial phrasing caused confusion between cytokines elevated in both groups versus those specifically upregulated in PLWH/COVID-19. To improve clarity, we have rewritten this paragraph to commutate the intended results: the revised paragraph is at lines 161–178) and now reads as follows:
Serum cytokines were analyzed in PLWH/COVID-19 and COVID-19-only patients with severe and moderate forms of the disease and control group. In both forms of disease and control group, 19 cytokines (IL-1β, IL-2, IL-1 α, IL-1Ra, IL-2Ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IL-16, IL-17, and IL-18) and 18 other cytokines (LIF, GM-CSF, IFN-α2, IFN-γ, bFGF, G-CSF, GM-CSF, HGF, LIF, M-CSF, MIF, b-NGF, PDGF-BB, SCF, SCGF-b, TNF- β , TRAIL, and VEGF) were measured. In addition, 12 chemokines (M-CSF, CCL2, CXCL9, CCL3, CCL4, CCL5, CCL7, CCL11, CCL27, CXCL1, CXCL10, CXCL12) were measured in PLWH/COVID-19, COVID-19-only and control groups.
Six (6) chemokines (CXCL9, CXCL10, CCL4, CCL5, CCL27, and CXCL12) and 8 cytokines (IL-1Ra, IL-2Ra, IL-3, IL-5, IL-9, IL-12p40, IL-15, and IL-16) were increased in both PLWH/COVID-19 and COVID-19-only groups (Figure 4A and 4C). Increased levels of cytokines (IL-1 α, IL-7, IL-17, and IL-18) and chemokines (CCL11, and CXCL1) were observed only in the COVID-19-only group, whilst PLWH/COVID-19, had increased levels of 4 cytokines (IL-5, IL-6, IL-9, and IL-15) and one chemokine (CXCL10) compared to COVID-19-only. Interestingly, CXCL10 was not increased in COVID-19-only. Also, G-CSF and VEGF were increased in COVID-19-only and PLWH/COVID-19 compared to the control.
Comment 4: Of the 9 HIV patients, the viral RNA in 4 patients was undetected. What was the difference in ILs of the two groups, and how was undetectable RNA associated with COVID-19 severity? Additionally, it becomes more important to present the ART components when viral RNA cannot be detected, as some of the ART components are directly related to IL level.
Response 4:
We appreciate the reviewer’s insightful comment. While we acknowledge the importance of comparing IL levels between patients with detectable and undetectable HIV RNA, our study was not designed to specifically stratify participants according to HIV viral load or ART regimen components. The small number of HIV-positive participants (n = 9), and the smaller subgroup with detectable viral RNA (n = 5), would make such statistical comparisons unreliable and potentially misleading due to limited statistical power. We have acknowledged this limitation and can be found at lines 229-235.
Nonetheless, all participants were receiving standard antiretroviral therapy (ART) in accordance with national HIV treatment guidelines, and those with undetectable RNA were considered virologically suppressed. Because of this uniformity in ART coverage and the exploratory nature of our study, we focused primarily on the broader trends of IL expression among HIV-positive and HIV-negative groups in the context of COVID-19 severity.
Comment 5: It is not clear why phylogenetic analysis was presented. It appears to have no connection to the main focus of the study. If the authors believe there is a relationship, it should be clearly outlined.
Response 5: We appreciate the reviewer’s comment and have clarified the purpose of including phylogenetic analysis in the Discussion. The analysis was conducted to verify that the HIV-1 strains circulating in our cohort belonged to the predominant subtype A6 circulating in Russia, thereby excluding subtype variability as a confounding factor influencing cytokine expression or disease severity. The revised text (lines 192–215) now explicitly explains this rationale:
In this pilot study, including 9 PLWH/COVID-19 and 9 COVID-19-only, we found more severe clinical outcomes and distinct pro-inflammatory cytokines in SARS-CoV-2-infected PLWH. To ensure that these immunological and clinical differences were triggered by Russian HIV strains, we performed a phylogenetic analysis of the HIV env gene sequences obtained from PLWH/COVID-19 patients. It has been demonstrated that HIV-1 circulates in Tatarstan, Russia, supporting previous findings (Kazennova et al., 2014). Four HIV sequences identified in this study clustered with the most prevalent HIV-1 A (315/332) subtype detected in Russia (Kazennova et al., 2014). The inclusion of this phylogenetic assessment was important to confirm the genetic homogeneity of HIV-1 isolates within the cohort and to exclude subtype-related confounding effects on cytokine expression or disease severity.
HIV-1 A is the second most dominant subtype after HIV-1 C, circulating globally (Williams et al., 2023). Although there is limited information on the unique clinical characteristics of each HIV-1 subtype, it is known that clinical presentation and disease outcome overlap and are modified by host genetics, pathogens, and environmental factors (Tough & McLaren, 2019). HIV-1 A suppresses the immune system, thereby affecting the outcome of COVID-19 infection (Rhodes et al., 2005). Our results therefore indicate that the elevated IL-6, IL-15, and IL-5 levels, as well as the higher frequency of severe COVID-19 in PLWH, are likely attributable to host–virus immune interactions rather than subtype variability. We also found that one HIV-1 isolate genetically differs from others, suggesting different variants are circulating in Russia. This assumption is supported by genetic analysis completed by Antonova et al., indicating an increased global genetic diversity of HIV-1 (Antonova et al., 2023). However, this genetic variability did not correspond to a distinct clinical pattern in our cohort, suggesting that subtype heterogeneity played a negligible role in the observed immune differences between PLWH/COVID-19 and COVID-19-only groups.
Comment 6: Line 94. It is not that patients were collected. It should be 'the patient samples' were collected.
Response 6: The sentence has been revised accordingly (line 94).
Comment 7: Minor - Line 84: The reference is missing. It just states (ref).
Response 7: The missing reference has been inserted:
Montazersaheb, S., Hosseiniyan Khatibi, S.M., Hejazi, M.S. et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J 19, 92 (2022). https://doi.org/10.1186/s12985-022-01814-1
Reviewer 2 Report
Comments and Suggestions for Authors1) The introduction while comprehensive could undergo some restructuring for better flow
2) Was the control group age and sex matched?
3) How was missing data handled if any?
4) a more in depth discussion of the statistics is needed, was any multiple comparison corrections performed?
5) The figure legends need to be improved for clarity.
6) Results are stated as significant but there are no p-values to show this
7) In the discussion there is speculation about the Omicron variant but there is no data to support this.
8) How does this study align with past studies on this topic
10) The English is hard to read and needs extensive revisions.
11) The fact that this is a small sample size needs to be discussed more as a limitation.
Author Response
We would like to thank the reviewer for the careful reading of our manuscript and for the constructive comments, which helped us to improve the clarity and scientific quality of our work. We have addressed all points raised, as detailed below. And all the changes made in the manuscript are highlighted in yellow.
Comment 1: The introduction while comprehensive could undergo some restructuring for better flow
Response 1: We appreciate the reviewer’s valuable suggestion. We have restructured the Introduction to improve the logical flow and readability. Specifically, we:
- Began with the global impact of COVID-19 and known risk factors.
- Introduced HIV infection and its relevance to COVID-19 outcomes.
- Summarized existing evidence and inconsistencies in the literature.
- Concluded with the rationale, knowledge gap, and objectives of the present study.
Comment 2: Was the control group age and sex matched?
Response 2: Yes, the control group was age- and sex-matched with the patient groups. As shown in Table 1, the mean ages of participants were comparable across the three cohorts (PLWH/COVID-19: 38.0 ± 11.9 years; COVID-19-only: 47.0 ± 12.6 years; Controls: 47.1 ± 13.7 years; p > 0.05). The sex distribution was also similar (PLWH/COVID-19: 44.4% male; COVID-19-only: 33.3% male; Controls: 66.7% male; p > 0.05).
Comment 3: How was missing data handled if any?
Response 3: We thank the reviewer for this question. Missing data were minimal in this pilot study. Cytokine and biochemical measurements were performed only for samples with complete clinical and laboratory information available at the time of collection. Cases with missing values for any of the analyzed parameters were excluded from the corresponding statistical comparisons and not included.
Comment 4: a more in-depth discussion of the statistics is needed, was any multiple comparison corrections performed?
Response 4: We thank the reviewer for this valuable comment. The updated statistic section now reads:
Statistical analyses were performed in the R environment (R-project, 2020, https://wwwr-project.org/, accessed November 1, 2020). The distribution of all quantitative variables was evaluated using the Shapiro–Wilk normality test. As most parameters were not normally distributed, non-parametric methods were used for all subsequent analyses. Differences between groups were assessed using the Kruskal–Wallis test, and p-values were adjusted for multiple comparisons using the Benjamini–Hochberg (BH) false discovery rate (FDR) procedure. Statistically significant differences between comparison groups were accepted as p < 0.05. Asterisks in figures indicate levels of significance (p < 0.05, p < 0.01, p < 0.001). (lines 374-382)
Comment 5: The figure legends need to be improved for clarity.
Response 5: We thank the reviewer for this suggestion.
All figure legends have been revised for improved clarity. Each legend now specifies the patient groups compared, units of measurement, statistical tests used, and significance thresholds. For multi-panel figures, each subpanel (A–D) is now described individually. These changes make the figures self-explanatory and consistent with formatting standards.
Comment 6: Results are stated as significant but there are no p-values to show this
Response 6: We thank the reviewer for this observation.
The statistical significance values were indicated in all figures using asterisks, as detailed in the figure legends (p < 0.05, p < 0.01, p < 0.001). To improve clarity, we have added explicit references to these p-value thresholds in the Statistical Analysis section and ensured that each figure legend now clearly defines the meaning of the asterisk notation.
Comment 7: In the discussion there is speculation about the Omicron variant but there is no data to support this.
Response 7: We thank the reviewer for this valuable observation. We agree that our study does not include genomic data on SARS-CoV-2 variants, and the reference to the Omicron variant was intended only as contextual information from published literature. To clarify this point and avoid over-speculation, we have revised the relevant paragraph in the Introduction to clearly indicate that this statement refers to previously published evidence and not to our own findings (lines 65-69)
Comment 8: How does this study align with past studies on this topic
Response 8: Our data are consistent with earlier studies showing enhanced pro-inflammatory cytokine responses and immune dysregulation in PLWH with SARS-CoV-2 infection (Ho et al., 2021; Amegashie et al., 2024). The observed elevation of IL-6 and IL-15 aligns with previous evidence linking these cytokines to disease severity and poor clinical outcomes in both HIV and COVID-19 (Del Valle et al., 2020; Swaminathan et al., 2016). Similarly, our findings of lipid metabolism disturbances and coagulopathy are in agreement with reports of metabolic dysregulation in PLWH and its contribution to severe COVID-19 (Feeney & Mallon, 2011; Dirajlal-Fargo et al., 2021).
We have added the following paragraph to the Discussion (lines 288–295):
« Overall, our findings are in agreement with prior studies demonstrating that both HIV and SARS-CoV-2 trigger systemic inflammation and immune activation. The elevation of IL-6, IL-15, and IL-5 in PLWH/COVID-19 mirrors previously reported cytokine signatures associated with hyperinflammation and adverse clinical outcomes in both infections. These results extend existing observations by highlighting that, even in patients on ART, persistent immune activation may predispose PLWH to severe COVID-19 outcomes»
Comment 10: The English is hard to read and needs extensive revisions.
Response 10: The manuscript was revised by the native speaker
Comment 11: The fact that this is a small sample size needs to be discussed more as a limitation.
Response 11: We agree with the reviewer. The limitation is stated at lines 229-235.
While our data suggests a trend where higher HIV load correlates with worse outcomes, the small sample size limits a definitive conclusion. The limited PLWH/COVID-19 sample size collected could be a result of the low prevalence of HIV in Tatarstan, there of the HIV prevalence is 395,5/100,000 population, August 2025. Also, a contributing factor is that samples were collected during the pandemic, where PLWH were observing the quarantine restrictions as they had immune compromised condition. As a result, there was a low number of patients hospitalized with HIV during the quarantine period.